CONFORMED COPY

PRICING SUPPLEMENT

PROHIBITION OF SALES TO EEA RETAIL INVESTORS – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (the "**EEA**"). For these purposes, a retail investor means a person who is one (or both) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU, as amended ("**EU MiFID II**"); or (ii) a customer within the meaning of Directive (EU) 2016/97, as amended, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of EU MiFID II. Consequently, no key information document required by Regulation (EU) No 1286/2014, as amended (the "**EU PRIIPs Regulation**") for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the EU PRIIPs Regulation.

PROHIBITION OF SALES TO UNITED KINGDOM RETAIL INVESTORS – The Notes are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise made available to any retail investor in the United Kingdom. For these purposes, a retail investor means a person who is not a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, as amended (the "**EUWA**") ("**UK MiFIR**"). Consequently, no disclosure document required by the FCA Product Disclosure Sourcebook ("**DISC**") for offering, selling or distributing the Notes or otherwise making them available to retail investors in the United Kingdom has been prepared and therefore offering, selling or distributing the Notes or otherwise making them available to any retail investor in the United Kingdom may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.

EU MiFID II product governance / Professional investors and eligible counterparties only target market – Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties and professional clients only, each as defined in EU MiFID II; and (ii) all channels for distribution of the Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Notes (an "**EU distributor**") should take into consideration the manufacturers' target market assessment; however, an EU distributor subject to EU MiFID II is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels.

UK MiFIR product governance / Professional investors and eligible counterparties only target market – Solely for the purposes of each manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook, and professional clients, as defined in UK MiFIR; and (ii) all channels for distribution of the Notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the Notes (a "**UK distributor**") should take into consideration the manufacturers' target market assessment; however, a UK distributor subject to the FCA Handbook Product Intervention and Product Governance Sourcebook is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturers' target market assessment) and determining appropriate distribution channels.

Notice to Ontario, Alberta and British Columbia permitted investors - The Notes may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), that are not individuals and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the

Notes must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the Offering Memorandum and this Pricing Supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal adviser.

3 September 2026

GSK Capital B.V.

(Legal Entity Identifier: 549300ZGXDBU2ZV6RP76)

Issue of EUR850,000,000 3.875 per cent. Notes due 2034

Guaranteed by GSK plc

under the £20,000,000,000 Euro Medium Term Note Programme

PART A - CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the terms and conditions of the Notes (the "**Conditions**") set forth in the Offering Memorandum dated 3 August 2026 (the "**Offering Memorandum**"). This document constitutes the Pricing Supplement of the Notes described herein for the purposes of the Conditions and must be read in conjunction with the Offering Memorandum in order to obtain all the relevant information. Full information on the Issuer, the Guarantor and the offer of the Notes is only available on the basis of the combination of this Pricing Supplement and the Offering Memorandum. Copies of the Offering Memorandum are available for viewing and may be obtained from the registered office of the Issuer at 79 New Oxford Street, London WC1A 1DG, United Kingdom and the Offering Memorandum has been published on the following website: www.gsk.com.

1.	(a)	Issuer:	GSK Capital B.V.
	(b)	Guarantor:	GSK plc
2.	(a)	Series Number:	35
	(b)	Tranche Number:	1
	(c)	Date on which the Notes shall be consolidated and form a single series:	Not Applicable
3.	Specified Currency or Currencies:		Euro ("**EUR**")
4.	Aggregate Nominal Amount		
	(a)	Series:	EUR850,000,000

(b) Tranche:	EUR850,000,000
5. Issue Price:	99.420 per cent. of the Aggregate Nominal Amount
6. (a) Specified Denominations:	EUR100,000 and integral multiples of EUR1,000 in excess thereof up to and including EUR199,000. No Notes in definitive form will be issued with a denomination above EUR199,000.
(b) Calculation Amount (in relation to calculation of interest in global form or registered definitive form, see Conditions):	EUR1,000
7. (a) Issue Date:	7 September 2026
(b) Interest Commencement Date:	Issue Date
8. Maturity Date:	7 September 2034
9. Interest Basis:	3.875 per cent. Fixed Rate
10. Redemption Basis:	Subject to any purchase and cancellation or early redemption, the Notes will be redeemed on the Maturity Date at 100 per cent. of their nominal amount
11. Change of Interest:	Not Applicable
12. Put/Call Options:	Issuer Residual Call Make-Whole Redemption by the Issuer Issuer Maturity Call
13. (a) Status of the Notes:	Senior
(b) Status of the Guarantee:	Senior
14. Date of applicable approval for issuance of Notes and Guarantee obtained:	18 May 2026 and 30 June 2026, respectively

PROVISIONS RELATING TO INTEREST (IF ANY) PAYABLE

15. Fixed Rate Note Provisions:	Applicable
(a) Rate(s) of Interest:	3.875 per cent. per annum payable in arrear on each Interest Payment Date
(b) Interest Payment Date(s):	7 September in each year up to and including the Maturity Date, commencing on 7 September 2027
(c) Fixed Coupon Amount(s) (and in relation to Notes in global	EUR38.75 per Calculation Amount

		form or registered definitive form, see Conditions):	
	(d)	Broken Amount(s) (and in relation to Notes in global form or registered definitive form, see Conditions):	Not Applicable
	(e)	Day Count Fraction:	Actual/Actual (ICMA)
	(f)	Determination Date(s):	7 September in each year
	(g)	Other terms relating to the method of calculating interest for Fixed Rate Notes:	Not Applicable
16.	Floating Rate Note Provisions:		Not Applicable
17.	Zero Coupon Note Provisions:		Not Applicable

PROVISIONS RELATING TO REDEMPTION

18.	Issuer Call:		Not Applicable
19.	Issuer Residual Call:		Applicable
		Residual Call Early Redemption Amount:	EUR1,000 per Calculation Amount
20.	Make-Whole Redemption by the Issuer:		Applicable from (and including) the Issue Date to (but excluding) 7 June 2034
	(a)	Make-Whole Redemption Margin:	0.150 per cent.
	(b)	Reference Bond:	DBR 2.600 per cent. due August 2034 (ISIN: DE000BU2Z031)
	(c)	Quotation Time:	5.00 p.m. Brussels time
	(d)	Reference Rate Determination Date:	The third Business Day preceding the relevant Make-Whole Redemption Date
	(e)	If redeemable in part:	Not Applicable
21.	Issuer Maturity Call:		Applicable. The Issuer Maturity Call Period Commencement Date is 7 June 2034 and Condition 6(e) and Condition 6(f) shall be construed accordingly
22.	Investor Put:		Not Applicable

23.	Final Redemption Amount of each Note:	EUR1,000 per Calculation Amount
24.	Early Redemption Amount per Calculation Amount payable on redemption for taxation reasons or on event of default:	EUR1,000 per Calculation Amount

GENERAL PROVISIONS APPLICABLE TO THE NOTES

25.	Form of Notes:	Bearer Notes: Temporary Bearer Global Note exchangeable for a Permanent Bearer Global Note which is exchangeable for Definitive Notes only upon an Exchange Event
26.	New Global Note:	Yes
27.	Intended to be held in a manner which would allow Eurosystem eligibility:	Yes. *Note that the designation "yes" simply means that the Notes are intended upon issue to be deposited with one of the ICSDs as common safekeeper and does not necessarily mean that the Notes will be recognised as eligible collateral for Eurosystem monetary policy and intra day credit operations by the Eurosystem either upon issue or at any or all times during their life. Such recognition will depend upon the European Central Bank being satisfied that Eurosystem eligibility criteria have been met.*
28.	Additional Financial Centre(s):	London
29.	Other terms or special conditions:	Condition 6(e) and Condition 6(f) shall be construed as set out in paragraph 21 above

Signed on behalf of the Issuer:

SIMON BURNS
By: ________________________________

Duly authorised

Signed on behalf of the Guarantor:

SIMON BURNS
By: ________________________________

Duly authorised

PART B - OTHER INFORMATION

1. **LISTING AND ADMISSION TO TRADING**

(i)	Listing and admission to trading:	Application has been made for the Notes to be admitted to trading on the London Stock Exchange's International Securities Market with effect from the Issue Date.
(ii)	Estimate of total expenses related to admission to trading:	£6,700

2. **RATINGS**

Ratings:	The Notes to be issued have been rated:
	S&P Global Ratings UK Limited: A Moody's Investors Service Limited: A2

3. **INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE**

Save for any fees payable to the Managers referred to below, and that the proceeds of the issuance of the Notes will be used in whole or in part to refinance a bridge loan facility provided by one or more of the Managers, so far as the Issuer is aware, no person involved in the issue of the Notes has an interest material to the offer. The Managers and their affiliates have engaged, and may in the future engage, in investment banking and/or commercial banking transactions with, and may perform other services for, the Issuer and the Guarantor and their affiliates in the ordinary course of business.

4. **YIELD**

Indication of yield:	3.961 per cent. per annum
	The yield is calculated at the Issue Date on the basis of the Issue Price. It is not an indication of future yield.

5. **OPERATIONAL AND OTHER INFORMATION**

(i)	ISIN Code:	XS3480671331
(ii)	Common Code:	348067133
(iii)	CFI:	See the website of the Association of National Numbering Agencies ("**ANNA**") or alternatively sourced from the responsible National Numbering Agency that assigned the ISIN
(iv)	FISN:	See the website of the ANNA or alternatively sourced from the responsible National Numbering Agency that assigned the ISIN

(v)	Any clearing system(s) other than Euroclear Bank SA/NV and Clearstream Banking S.A. and the relevant identification number(s):	Not Applicable
(vi)	Name(s) and address(es) of the initial paying agent(s):	Citibank, N.A., London Branch Citigroup Centre Canada Square Canary Wharf London E14 5LB United Kingdom
(vii)	Names and addresses of additional Paying Agent(s) (if any):	Not Applicable
(viii)	Use of proceeds:	Repayment of facility related to acquisition of Nuvalent, Inc. and general corporate purposes, including the refinancing of existing debt

6. **DISTRIBUTION**

(i)	Method of distribution:	Syndicated
(ii)	If syndicated:	
	(A) Names of Managers:	**<u>Global Coordinators and Joint Lead Managers:</u>** BNP PARIBAS BofA Securities Europe SA **<u>Joint Lead Managers:</u>** Banco Santander, S.A. HSBC Continental Europe Standard Chartered Bank **<u>Passive Bookrunners:</u>** Barclays Bank PLC Citigroup Global Markets Europe AG Deutsche Bank Aktiengesellschaft Goldman Sachs Bank Europe SE J.P. Morgan SE Mizuho Bank Europe N.V. Morgan Stanley & Co. International plc
	(B) Stabilisation Manager(s) (if any):	Not Applicable
(iii)	If non-syndicated, name of Dealer:	Not Applicable

(iv)	Whether TEFRA D or TEFRA C rules applicable or TEFRA rules not applicable:	TEFRA D
(v)	US Selling Restrictions:	Reg. S. Compliance Category 2; TEFRA D
(vi)	Prohibition of sales to EEA Retail Investors:	Applicable
(vii)	Prohibition of sales to United Kingdom Retail Investors:	Applicable